US 10016463
Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
granted A61KA61K31/5585A61K35/02
Quick answer
US patent 10016463 (Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells) held by United Therapeutics Corporation expires Mon Jul 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- United Therapeutics Corporation
- Grant date
- Tue Jul 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K31/5585, A61K35/02, A61K35/28, A61K35/44